FDA Approves First SMA Drug That Targets Muscle Loss, Not Just Nerves
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
/ 26 items
#NVS↓
Major Novartis Shareholder Calls for Board Shake-Up After Two Failed Drug Trials
Artisan Partners wants Novartis board changes after Avidity’s del-desiran and pelacarsen failed late-stage trials and wiped out $30B in value.
Novartis Failure Raises Questions for Dyne’s 2027 DM1 Readout
Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.
Novartis Muscle-Disease Drug Misses Phase 3 Goal, Shares Drop After $12 Billion Avidity Bet
Novartis del-desiran missed its Phase 3 HARBOR goal in DM1. Shares fell ~9–10% a day after a cholesterol-drug miss. Sarepta and Dyne also dropped.
Amgen Slides After BMO Downgrade and Rival Heart-Drug Miss
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
Novartis, Ionis Heart Drug Misses Phase 3 Goal Despite Cutting Lp(a)
Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.